A novel disintegrin protein from Naja naja venom induces cytotoxicity and apoptosis in human cancer cell lines in vitro

Thangam, Ramar; Gunasekaran, Palani; Krishnasamy, Kaveri; Sridevi, G.; Kannan, R.; Paulpandi, Manickam; Kannan, Soundarapandian

doi:10.1016/j.procbio.2012.04.020

Cited by 57 publications

(20 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After treatment with 2‐pyrrolidinone at their IC 50 concentrations (1.5 µg/ml and 2 µg/ml for HeLa and PC‐3 cells, respectively) for a period of 24 h, morphological changes in the cells were observed ( Fig . B ) (Thangam et al ., ).…”

Section: Resultsmentioning

confidence: 99%

“…Subsequently, 1:100 volumes of 20 mg/ml RNase were added, and the mixture was incubated at 37 °C for 1 h. Propidium iodide was added to a final concentration of 50 µg/ml and incubated for 10–20 min at RT. The stained cells were analyzed for DNA histograms and for cell cycle phase distribution using flow cytometry (Becton Dickinson Immunocytometry System) (Thangam et al ., ; Sundarraj et al ., ).…”

Section: Methodsmentioning

confidence: 97%

“…Penicillin and streptomycin (100 IU/100ug) were adjusted to 1 ml/l. The cells were maintained at 37 °C with 5% CO 2 in a humidified CO 2 incubator (Thangam et al ., ; Sundarraj et al ., ).…”

Section: Methodsmentioning

confidence: 99%

“…The optical density was measured at 620 nm in an ELISA multi-well plate reader (Thermo Multiskan EX, USA). The OD value was used to calculate the percentage of viability (Mosmann 1983;Thangam et al, 2012).…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Antioxidant and In Vitro Anticancer Effect of 2‐Pyrrolidinone Rich Fraction of Brassica oleracea var. capitata Through Induction of Apoptosis in Human Cancer Cells

Thangam

Suresh

Rajkumar

et al. 2013

Phytotherapy Research

Self Cite

View full text Add to dashboard Cite

The aim of this study was to analyze if the 2-pyrrolidinone rich fraction of Brassica oleracea var. capitata exhibiting antioxidant and in vitro anticancer activities. 2-Pyrrolidinone is an active compound present in Brassica oleracea var. capitata. Our findings explored the potential use of 2-pyrrolidinone in cancer treatment. This compound was identified and isolated by gas chromatography-mass spectrometry and high-performance liquid chromatography from the leaf of Brassica oleracea var. capitata. The resultant rich active compound exhibited in vitro cytotoxicity in HeLa and PC-3 human cancer cell lines, and it also exhibited antioxidant activity in cell free assays. DAPI staining, an apoptotic analysis and cell cycle analysis were performed to evaluate the anticancer activity of 2-pyrrolidinone against the above cell lines. The IC50 value of 2-pyrrolidinone was determined to be of 2.5 µg/ml for HeLa, 3 µg/ml for PC-3 cells at 24 h and 1.5 µg/ml for HeLa and 2 µg/ml for PC-3 cells at 48 h, respectively. However, cell cycle analysis revealed that the anti-proliferative effects of the 2-pyrrolidinone were mediated through cell cycle arrest in the G0/G1 phase. These results from the current study suggest that the 2-pyrrolidinone have potential anticancer effects, which will lead to the development of new anticancer agents for arresting cancer cells growth in vitro.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 97%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Antioxidant and In Vitro Anticancer Effect of 2‐Pyrrolidinone Rich Fraction of Brassica oleracea var. capitata Through Induction of Apoptosis in Human Cancer Cells

Thangam

Suresh

Rajkumar

et al. 2013

Phytotherapy Research

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition to anti‐platelet aggregation activity, some disintegrins have also cytotoxic effects. Indeed, an isolated disintegrin (64 kDa) from Naja naja venom induced cytotoxic effects on several human cancer cell lines including breast cancer (MCF‐7), lung cancer (A549), and liver cancer (HepG2) …”

Section: Discussionmentioning

confidence: 99%

Isolation and characterization of an anti‐leishmanial disintegrin from Cerastes cerastes venom

Allane

Oussedik-Oumehdi

Harrat

et al. 2017

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Investigating new antimicrobial and antiparasitic components from Viperidae venoms represents an alternative therapeutic strategy. In this study, we report the characterization of a disintegrin isolated from Cerastes cerastes venom, exhibiting antiparasitic activity on Leishmania infantum promastigotes. Indeed, isolated disintegrin, referred to Disintegrin_Cc, induced 84.75% of parasiticidal activity and deep morphological alterations on the parasites. SDS-PAGE analysis indicated that this disintegrin was homogenous. This dimeric disintegrin of 14,193.97 Da contains an RGD domain and four intramolecular disulfide bridges. It presents a high percentage of identity with other related snake disintegrins. Predicted 3D structure indicated that this peptide shares partial homology with well-known active antimicrobial peptides. Disintegrin_Cc inhibited 80% of arachidonic acid-induced platelet aggregation. The obtained results suggest that the isolated molecule plays a dual role as a disintegrin and as an anti-leishmanial compound. This component could be useful as a drug in the treatment of leishmaniasis.

show abstract

Snake venom toxins: Potential anticancer therapeutics

Offor,

Piater

2023

J of Applied Toxicology

View full text Add to dashboard Cite

Snake venom contains a cocktail of compounds dominated by proteins and peptides, which make up the toxin. The toxin components of snake venom attack several targets in the human body including the neuromuscular system, kidney and blood coagulation system and cause pathologies. As such, the venom toxins can be managed and used for the treatment of these diseases. In this regard, Captopril used in the treatment of cardiovascular diseases was the first animal venom toxin‐based drug approved by the US Food and Drug Administration and the European Medicines Agency. Cancers cause morbidity and mortality worldwide. Due to side effects associated with the current cancer treatments including chemotherapy, radiotherapy, immunotherapy, hormonal therapy and surgery, there is a need to improve the efficacy of current treatments and/or develop novel drugs from natural sources including animal toxin‐based drugs. There is a long history of earlier and ongoing studies implicating snake venom toxins as potential anticancer therapies. Here, we review the role of crude snake venoms and toxins including phospholipase A2, L‐amino acid oxidase, C‐type lectin and disintegrin as potential anticancer agents tested in cancer cell lines and animal tumour models in comparison to normal cell lines. Some of the anti‐tumour activities of snake venom toxins include induction of cytotoxicity, apoptosis, cell cycle arrest and inhibition of metastasis, angiogenesis and tumour growth. We thus propose the advancement of multidisciplinary approaches to more pre‐clinical and clinical studies for enhanced bioavailability and targeted delivery of snake venom toxin‐based anticancer drugs.

show abstract

A novel disintegrin protein from Naja naja venom induces cytotoxicity and apoptosis in human cancer cell lines in vitro

Cited by 57 publications

References 16 publications

Antioxidant and In Vitro Anticancer Effect of 2‐Pyrrolidinone Rich Fraction of Brassica oleracea var. capitata Through Induction of Apoptosis in Human Cancer Cells

Antioxidant and In Vitro Anticancer Effect of 2‐Pyrrolidinone Rich Fraction of Brassica oleracea var. capitata Through Induction of Apoptosis in Human Cancer Cells

Isolation and characterization of an anti‐leishmanial disintegrin from Cerastes cerastes venom

Snake venom toxins: Potential anticancer therapeutics

Contact Info

Product

Resources

About